Madrigal Pharmaceuticals (NASDAQ:MDGL) Rating Reiterated by JMP Securities
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report)‘s stock had its “market outperform” rating reiterated by investment analysts at JMP Securities in a report released on Friday, Benzinga reports. They currently have a $347.00 target price on the biopharmaceutical company’s stock. JMP Securities’ price objective suggests a potential upside of 46.70% from the stock’s current price. […]
More Stories
Critical Review: i-80 Gold (IAUX) & Its Rivals
i-80 Gold (NYSE:IAUX – Get Free Report) is one of 114 publicly-traded companies in the “Gold & silver ores” industry,...
Hillman Solutions Corp (NASDAQ:HLMN) Receives $14.20 Average Target Price from Analysts
Hillman Solutions Corp (NASDAQ:HLMN – Get Free Report) has earned an average rating of “Moderate Buy” from the six ratings...
Equity Residential (NYSE:EQR) Receives Consensus Rating of “Hold” from Analysts
Equity Residential (NYSE:EQR – Get Free Report) has been assigned a consensus rating of “Hold” from the nineteen brokerages that...
Comparing NLS Pharmaceutics (NASDAQ:NLSP) and Atossa Therapeutics (NASDAQ:ATOS)
Atossa Therapeutics (NASDAQ:ATOS – Get Free Report) and NLS Pharmaceutics (NASDAQ:NLSP – Get Free Report) are both small-cap medical companies,...
Contrasting Globalstar (GSAT) & Its Rivals
Globalstar (NYSEARCA:GSAT – Get Free Report) is one of 32 publicly-traded companies in the “Communication services, not elsewhere classified” industry,...
Head-To-Head Contrast: AIM ImmunoTech (NYSE:AIM) versus INmune Bio (NASDAQ:INMB)
INmune Bio (NASDAQ:INMB – Get Free Report) and AIM ImmunoTech (NYSE:AIM – Get Free Report) are both small-cap medical companies,...